Lori Payton
Chief Development OfficerDr. Lori Payton, Ph.D., is Chief Development Officer of Yarrow Bioscience, Inc. Dr. Payton served as Senior Vice President of Development Operations & Strategy of AlloVir, Inc. since May 2022 until May 2022. She drives the execution of AlloVir’s clinical programs and strategic decision making around the company’s development portfolio. She has experience in strategic planning, portfolio management and advancing new therapies from preclinical stages through commercialization. Most recently, Dr. Payton served as Senior Vice President, Strategy, Portfolio and Program Management at Sage Therapeutics, where she led generation of the R&D strategy and portfolio planning process that informed investment in the Sage pipeline. Dr. Payton previously served as Vice President and Global Medicine Team Leader at Alexion Pharmaceuticals, where she led a cross-functional team in the planning and execution of development programs that led to the achievement of global registrations within industry-leading timelines. Prior to Alexion, she spent years at Pfizer in roles spanning the entire drug development continuum across multiple therapeutic areas. Dr. Payton has a PhD in pharmacology and experimental therapeutics from Boston University School of Medicine and a BA in biology from Wheaton College.
Positions
- Company NameYarrow Bioscience, Inc.Stock CodeYARWPositionChief Development Officer
